adesso SE (ADN1) Fair Value & Analysis
Technology · DE · Market cap €388M
Fair value as of: Jun 24, 2026
Analysis
adesso SE (ADN1) currently trades at €50.40, while our model-based Fair Value estimate is €59.48 — implying the stock looks roughly 18.0% undervalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
adesso SE, together with its subsidiaries, provides IT services in Germany, Austria, Switzerland, and internationally. It operates through two segments, IT Services and IT Solutions. The company offers industry-specific IT consulting and software development services; and distributes software products and industry-specific or industry-neutral solutions. The company provides application management, data and analytics, digital and customer experience, interaction room, IT management and organizational consulting, SmartShore, security, and other services. The company serves automotive, banks/financial services, utilities, healthcare, retail, life sciences, lottery, manufacturing, media and entertainment, food, exhibition, sports, public authorities, public transportation, and insurance industries. adesso SE was founded in 1997 and is headquartered in Dortmund, Germany.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is adesso SE (ADN1) undervalued?
What is the fair value of ADN1?
What is the quality score of ADN1?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.